Accendra Health says Q2 2026 results miss forecast on weaker revenue growth, slower collections recovery

Revenue excluding the large commercial payor exit rose 2%; sleep grew about 5.5%, diabetes 4%, while respiratory and wound declined.

Adjusted EBITDA was just over $60 million. The collections “waterfall” reduced revenue and earnings by about $10 million in Q2, and $20 million in H1.

Accounts receivable rose as certain commercial insurers’ audit-related process issues slowed cash receipts; improvement efforts were trending toward resolution in Q3.

Full-year outlook was cut to revenue of $2.45 billion-$2.55 billion, adjusted EBITDA of $300 million-$320 million, and free cash flow expected breakeven to slightly positive.

Accendra Health’s Q2 2026 results missed internal expectations, citing weaker-than-planned revenue growth, slower cost-save timing, and slower collections recovery.